NCT05292950View on ClinicalTrials.gov

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

PHASE1TerminatedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

November 12, 2024

Study Completion Date

November 12, 2024

Conditions
AsthmaChronic Obstructive Pulmonary Disease
Interventions
DRUG

ARO-MUC5AC

single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution

DRUG

Placebo

calculated volume to match active treatment by inhalation of nebulized solution

Trial Locations (13)

1010

Research Site 1, Auckland

1051

Research Site 2, Auckland

4101

Research Site 2, South Brisbane

6009

Research Site 1, Nedlands

10700

Research Site 1, Bangkok

14647

Research Site 3, Bucheon-si

54907

Research Site 2, Jeonju

15-010

Research Site 1, Bialystok

31-455

Research Site 2, Krakow

32-600

Research Site 3, Oświęcim

04763

Research Site 1, Seoul

08017

Research Site 1, Barcelona

M23 9QZ

Research Site 1, Wythenshawe

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY